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Introduction
Among the several merits that must be ascribed to the Revised
European–American Lymphoma (REAL) classification [1], the
most relevant from a therapeutic standpoint is that it has ulti-
mately allowed clinicians all over the world to fully compare the
results of clinical trials conducted elsewhere. Therefore, it is not
surprising that it was included almost untouched within the current
WHO classification of Tumours of Haematopoietic and Lymphoid
Tissues [2]. All previous lymphoma classifications had failed in
this scope, mainly owing to the different language and concepts
used by pathologists and clinicians in different countries to refer
to the variegate panorama of lymphoid tumors.
Meanwhile, the continuous effort towards the refinement of
lymphoma patients’ prognosis systems has also succeeded in
elaborating new and better prognostic indeces, such as the Interna-
tional Prognosis Index (IPI) [3] and, perhaps, the more recent
Follicular Lymphoma International Prognostic Index (FLIPI) [4].
It is indeed expected that the better categorization of patients,
which is intrinsic to the systematic and broad use of these scores,
will help to reach higher overall cure rates by calibrating disease
treatment to the real needs of the individual patient. In this respect,
the concomitant effort to objectively combine ‘traditional’, bio-
logical and clinical prognostic factors with the astonishingly
attractive findings of lymphoma genome profiling [5, 6] seems to
represent another crucial step towards improving the process of
selecting the best possible treatment. Of course, this ongoing
effort might even confuse the whole scenario of lymphoma man-
agement in the short-term, but the ultimate hope is that it will
prove invaluable in clarifying a number of concepts. Among them
for instance, in a time of rapidly aging population, the concept of
the ‘elderly patient’ is still too vague, undefined and often
neglected.
Over the last two decades, it has become increasingly clear that
intensified treatment does not necessarily translate into better clin-
ical results. In particular, the unique goal to be pursued should
remain that of curing as many patients as possible with as little
treatment as possible. However, this lesson has apparently only
been applied dose- and field extension-wise to radiation treatment
(RT), whereas the same attention has not always been given to
chemotherapy (CHT) dose intensity reduction. This fact, aside
from the obvious issue of short- and long-term toxicity in general,
has generated paradoxical situations such as that of Hodgkin’s
disease (HD) and follicular lymphoma (FL). In the case of the
highly curable HD, aggressive CHT regimens [7–9] have erased
the significance of any prognostic factor at diagnosis [10, 11],
while increasing both the overall toxicity and the second neo-
plasm frequency, without abolishing in principle the risk of
progression, resistance or relapse. The only logical conclusion
that can be drawn from these facts is that, currently, an important
fraction of HD patients may be overtreated [12]. On the other
hand, in the case of the substantially incurable FL, the number of
treatment options and the tendency towards chemotherapy inten-
sification [13–17] have led to a confusing situation where a
number of patients are also possibly either over or poorly treated,
without a clear-cut improvement in either cure or survival rates.
An important area of both new hope and concern is the growing
number of biological therapies that have come into their own.
Among them, passive, active, adoptive and radio-immunotherapy
share great promise and raise important questions in terms of
appropriateness of their clinical use. It will be advisable to study
carefully their effective applications to lymphoma treatment, in
order to possibly avoid the unfortunate experience with α-inter-
feron, which paradoxically is still used in individual patients, but
is kept out of most clinical trials.
All in all, both the recent and the expected further findings in
lymphoma classification, prognostic systems and treatment
options justify being optimistic of a substantial improvement of
the already relatively satisfactory results achieved in lymphoma
management.
Hodgkin’s disease
Currently, the major management issues related to HD concern
the treatment options for patients presenting with the following:
stage IA, stage IB and II, stage III and IV, elderly age, residual
mediastinal lesions, and relapse or resistance. In addition, nearly
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half a century after the first HD cases were cured by RT alone, the
exact role of this treatment option is now, more than ever, under
intense scrutiny.
Over the last couple of years, at least four studies have been
conducted and published, while others have been started, in order
to possibly contribute to the clarification of the way a patient
should be treated at diagnosis, mainly depending on the Ann
Arbor stage only.
Press et al. [18] have randomized as many as 348 patients with
either IA or IIA, supradiaphragmatic HD to receive either subtotal
lymphoid irradiation (STLI) or three cycles of doxorubicin- and
vinblatine-based CHT plus STLI. Response-wise, the latter
treatment option proved dramatically superior in terms of both
failure-free survival (94% versus 81%) and relapse rate (P < 0.001).
However, the relatively short follow-up time (3.3 years) does not
allow a complete assessment of other parameters, such as overall
survival (OS) and long-term toxicity.
In Germany, Sieber et al. [19] randomized 996 patients with
stage I–III disease (excluding those in stage I–II with no risk
factors) to receive, in combination with extended-field RT, either
rapidly alternating COPP/ABV/IMEP or conventional alternating
COPP/ABVD. With a median follow-up time of 7 years, no differ-
ences at all were found in terms of complete responses (CR = 94%
versus 93%, respectively), freedom from treatment failure (79%
versus 80%, respectively), OS (88% in both arms) and second
neoplasm frequency (22 events in both arms), or serious infections
and toxic deaths.
Horning et al. [8] recently updated the results of their prospective
clinical trial on the use of Stanford V CHT regimen plus RT (on
bulky sites only) for HD patients with either stage I–II with bulky
mediastinal mass presentation or stage III–IV. With a median
follow-up of 5.4 years, the 5-year freedom from progression
(FFP) was 89% and the OS was 96%, with a highly significative
difference in terms of FFP for the patients with prognostic score
[10] <3 (94% versus 75%, respectively; P < 0.0001). Considering
also that no secondary leukemia has occurred yet, as many as
46 pregnancies have been recorded instead ever since and the
freedom from second relapse for the 16 relapsed patients was
69%, high expectations suggest the ongoing Intergroup trial
(E2496) randomizing HD patients should receive either standard
ABVD or Stanford V (both with and without RT).
In fact, a recent preliminary report, characterized by an unex-
pectedly low response rate of HD patients to the Stanford V regimen,
is further confusing the scenario. Levis et al. [20] randomized 355
advanced stage (IIB–IV) HD patients to receive standard ABVD,
Stanford V or MOPP/EBV/CAD (MEC), each followed by RT on
residual and/or bulky disease sites. At the most recent interim
evaluation, as many as 272 patients were evaluable (ABVD = 98;
MEC = 83; Stanford V = 91), and the main clinical features were
well balanced among the three groups. The CR rates (CR + uncon-
firmed CR) were 70%, 71% and 58%, respectively, prior to RT
and 89%, 92% and 73%, respectively, following RT completion.
In both cases, ABVD and MEC showed better results (P < 0.01)
than Stanford V. Furthermore, MEC proved significantly more
toxic than the other two CHT regimens.
Finally, Radford et al. [21] randomized 282 HD patients either
in stage I–II (with bulky mediastinal presentation and/or B
symptoms) or III–IV to receive either ChlVPP/EVA or VAPEC-B
(both followed by RT on residual and/or bulky disease sites). With
a median follow-up time of 4.9 years, the superiority of the former
CHT regimen has been rapidly and clearly demonstrated in terms
of 5-year FFP (82% versus 62%, respectively), event-free survival
(EFS = 78% versus 58%, respectively) and OS (89% versus 79%,
respectively). However, it appears that, in the subset of patients
with prognostic score <3, the two regimens are equivalent.
All in all, these data seem to once again point out that when
treating HD patients, a little more attention should be paid at
diagnosis to their prognostic factors than only to the highest CR
rates achieved by each CHT regimen. Otherwise, the risk of
paying too high a global price for overtreatment appears to be
excessive. In addition, the same concept should be applied to
limiting the use of adjuvant RT in both early and advanced stage
HD [12].
In general, it is far from unreasonable to treat HD patients
presenting in stage IA without unfavorable prognostic factors with
RT alone. Likewise, patients presenting with stage IB–II disease
may be well treated with ABVD plus RT on residual and/or bulky
disease sites only. On the other hand, the quest for the best pos-
sible treatment for HD patients presenting with stage III–IV
disease is far from over. Save the BEACOPP [7] regimen, which
is however characterized by higher short- and long-term toxicity
[22], no other CHT schema has yet proved to be superior to the
ABVD regimen. Therefore, other randomized trials such as the
above-mentioned E2496 are warranted.
As for the treatment of elderly patients with HD, the lack of
clear-cut data from randomized trials, as well as the difficulty in
establishing a common ground about the age limit past which a
patient should be considered elderly, mean that each group’s
experience ends up having some, but not much, scientific merit. In
our experience, the VBM regimen [23], eventually followed by
RT on residual and/or bulky disease sites, is reliable and relatively
efficacious for HD patients above the age of 65 years.
The diagnostic management of residual mediastinal lesions
following HD treatment has recently been revolutionized by the
advent of [18F]fluorodeoxyglucose positron emission tomography
(FDG PET). The very few [24] or even absent (our unpublished
data) cases of false-negative FDG PET reported, together with the
equally lower and lower number of false-positives [24] and the
greater experience being gained by FDG PET specialists, are
setting the stage for whole-body FDG PET to become a funda-
mental tool in HD patient management. In particular, its role in
association with computed tomography scans seems to be pivotal
in the restaging of patients with mediastinum and abdomen bulky
disease presentation. In this setting, that is following CHT with or
without RT, its specific ability to both analyze residual masses and
discriminate between active disease and fibrosis/sclerosis ends up
being prognostically decisive in most, if not all, cases. This con-
cept is very important in the decision-making process, which may
or may not include further treatment for patients with disease
persistance after the induction phase. In addition, FDG PET could
prove to be an early imaging predictive factor allowing stratifi-
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cation of responding and non-responding patients after few
courses of chemotherapy [25]. However, it is clear that whenever
FDG PET is felt to potentially increase HD patient management
quality, it should be performed at diagnosis as well, in order to
allow clear-cut comparisons with those carried out at the time of
restaging/follow-up.
Concerning RT, its role in advanced stage HD patients seems to
be irrelevant in terms of OS and relapse-free survival (RFS), as
shown by a recent European Organisation for Research and Treat-
ment of Cancer study [26]. In this trial, a first detailed analysis
showed that involved-field RT (IF-RT) did not improve RFS and
OS in patients who had already achieved a CR with the MOPP/
ABV regimen. Remarkably, though, those patients who had
obtained a partial response (PR) and were subsequently treated
with additional IF-RT had comparable overall outcome to those
who had reached a CR. Once again, these data would suggest that,
save for stage IA HD patients, RT might be reserved to all cases
either presenting with bulky disease at diagnosis or achieving a
PR following first-line CHT.
Finally, relapsing, resistant and primary progressive HD patients
still pose one of the most serious challenges to the hematology/
oncology scientific community [9]. According to recent data from
the German Hodgkin’s Lymphoma Study Group, primary
progressive HD patients >50 years old, who have both a poor
Karnofsky performance score and fail to attain a temporary remis-
sion on first-line treatment, have an extremely poor prognosis and
should be considered for high-dose CHT (HDCT) followed by
autologous stem-cell transplantation (ASCT) [27]. The same
group also reports that similar conclusions should be drawn for
early relapsing HD patients, particularly those who present with
advanced disease and anemia at the time of relapse [28].
It is clear that, in all poor-prognosis HD patients, the only current
hope for cure remains based on the possible success of HDCT
followed by either ASCT [29] and/or non-myeloablative,
reduced-conditioning, allogeneic SCT [16, 17]. In fact, in con-
strast to non-Hodgkin’s lymphoma (NHL), the possible impact of
novel treatment modalities including new drugs, immunotherapy
and radio-immunotherapy appears not yet to be in the making.
Diffuse large B-cell lymphoma
Over the last decade, the first and foremost problem associated
with the management of diffuse large B-cell lymphoma (DLBCL)
has been how to move on from the shocking results of two ran-
domized studies conducted by Fisher and colleagues. These trials
proved that, for the treatment of aggressive NHL, third-generation
CHT regimens were not statistically superior to CHOP [30], and
that three cycles of CHOP were statistically superior to eight,
provided that these three cycles of CHT were followed by IF-RT
[31]. Ever since, a number of trials have been conducted either to
attempt to refute these data, by also comparing standard CHOP
with other treatment options, or as though these data did not exist
at all, by either exploring therapeutic approaches other than
CHOP or integrating CHOP with other therapeutic agents such as
anti-CD20 monoclonal antibodies (R-CHOP). Regarding localized
DLBCL, Fillet et al. [32] compared four cycles of CHOP with four
cycles of CHOP followed by IF-RT. In that study, 455 patients
were randomized to receive each treatment option, and 5-year
EFS and OS were not different. The authors concluded that IF-RT
following four cycles of CHOP added no benefit. Meanwhile, an
update of the Southwest Oncology Group experience [31] with a
follow-up in excess of 8 years now shows that PFS and OS curves
have merged at 7 and 9 years, respectively [33].
As far as the combination of CHOP with passive immuno-
therpay is concerned, Vose et al. [34] first showed that the addition
of rituximab to standard CHOP neither worsened CHT efficacy
nor added any toxicity supplement to aggressive NHL patients.
Even more compelling evidence in favor of this association was
then provided by Coiffier et al. [35] in the elderly, in this case
>60 years old, aggressive NHL patients. In particular, with a
follow-up of 2 years, they found that in a randomized setting, the
addition of rituximab to CHOP increased the CR rate from 63% to
76% (P = 0.005), the EFS from 39% to 57% (P < 0.001) and the
OS from 57% to 70% (P = 0.007). Whether the further addition of
rituximab alone as a maintainance treatment may exert a substantial
clinical effect in this as well as in many other lymphoma settings is
one of the most urgent questions that needs to be answered
through randomized, controlled, phase III clinical trials.
On the other hand, and again in aggressive NHL patients
>60 years old, Mainwaring et al. [36] surprisingly reported some-
what better results using a CHT regimen including mitoxantrone
rather than doxorubicin. In a BNLI-sponsored, randomized trial
comparing PAadriaCEBO with PMitCEBO, and with a 4-year
follow-up, the latter appeared to be superior in terms of overall
response (OR) rate (78% versus 69%; P = 0.05) and OS (50%
versus 28%; P = 0.0067), but not in terms of CR rate and RFS.
In the substantial absence of a consensus CHT regimen
accepted worldwide to treat aggressive NHL in general, and
DLBCL in particular, at diagnosis, more effort appears to have
been placed in possibly identifying DLBCL subtypes characterized
by important prognostic differences. For instance, Wilder et al.
[37] prospectively confirmed that, at diagnosis, doxorubicin-
based CHT with or without IF-RT can be considered an acceptable
option only for DLBCL patients with an IPI score <3. Meanwhile,
Wilson et al. [38] have suggested that dose-adjusted EPOCH
seems to kill DLBCL cells more effectively than a CHOP-based
regimen, and this fact might prove quite important, particularly in
the light of the possible identification of DLBCL subsets charac-
terized by poorer prognosis, such as bcl-2-positive [39] and CD5-
positive [40] DLBCL.
In the last few years, DLBCL has aroused a great deal of interest
among researchers, becoming a model for all studies on malignant
lymphomas. Its prevalence has facilitated the collection of large
series of cases for the application of novel and sophisticated tech-
niques, such as gene expression profiling and tissue microarrays.
These techniques have confirmed the heterogeneity of the process,
which had already been envisaged through cell morphology.
However, converse to the latter, they have provided for the first
time criteria for useful DLBCL subclassification, allowing the
possible identification of subgroups of patients with different
prognoses and different responses to the therapies already available.
In addition, they have made feasible the understanding of the
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molecular alterations that may be at work in each individual
patient. This fact is likely to bring much closer the final goal of
developing new drugs and tailored strategies capable of selec-
tively blocking the aberrant pathways involved in the initiation,
development and progression of the tumor [41].
Regarding the imaging field, PET scanning is a promising
method for identifying patients that, after induction treatment, can
or cannot be considered to be in CR. Thus, PET has to be considered
an important technique for tailoring the specific treatment depending
on the presence or absence of residual disease. In particular, most
PET-positive patients at the end of the induction treatment relapse
within the first 2 years [42]. In addition, early assessment with
PET scan in patients with untreated aggressive NHLs may play a
role in predicting the ultimate patient outcome [43].
Finally, as far as poor-prognosis, relapsed, resistant or progres-
sive DLBCL patients are concerned, while waiting for radio-
immunotherapy [44] to possibly exert a tangible role, at least for
some of them, ASCT remains the favored therapeutic option of
most clinicians [45, 46]. In this light, of some interest are the
recent data reported by the GELA group on the better outcome of
patients receiving CHT with high dose intensity prior to ASCT
[47] and those reported by Vose et al. [48] on the lack of prog-
nostic impact by the choice of either peripheral blood or bone
marrow as a source for ASCT. In contrast, what seems to matter
more is that either source of hematopoietic precursors could be
MRD-negative by molecular analysis [48]. In vivo purging with
rituximab therapy has been shown to be effective in follicular
lymphoma patients [49], most of them showing a disappearance
of bcl-2-positive cells in the harvest. However, no such marker
exists in DLBCL, and the proportion of patients with circulating
lymphoma cells is conspicuously lower than in indolent lymphoma.
Thus, the interest in this option remains disputable, and no conclu-
sive evidence in its favor has yet been presented.
Although there is consistent evidence for the efficacy of ASCT
in patients with CHT-sensitive relapse, the role of transplantation
as first-line therapy in PR or CR cases remains uncertain. In
particular, previous randomized studies reported by Santini et al.
[50] and Haioun et al. [47] suggested that ASCT should be
restricted to intermediate-/high-risk and high-risk groups as
defined by the IPI. However, we believe that such a hypothesis has
to be firmly confirmed in subsequent prospective randomized
trials, particularly in the light of other recent data suggesting the
need for IPI age adjustment in relapsed and primary refractory
DLBCL patients undergoing ASCT [51].
Finally, immunotherapy has begun to gain interest in the setting
of DLBCL as well, although the very first preliminary results
seem to indicate the need for complex approaches, such as that of
combining adoptive transfer of co-stimulated T cells and vaccine
strategies in order to possibly achieve clinical efficacy [52].
Mantle cell lymphoma
Nowadays, the only positive feature of mantle cell lymphoma
(MCL) remains its relatively low epidemiological incidence [2].
As a matter of fact, from a therapeutic standpoint, most clinical
trials raise only slight hopes, and not always, while no real
progress has yet been made.
Possibly the most negative evidence emerging recently was
reported by Howard et al. [53], who treated 40 newly diagnosed
MCL patients with R-CHOP. Their findings seem to indicate that
not even the tumor-specific bcl-1/IgH rearrangement disappearance
according to qualitative PCR is enough to predict a better outcome
in terms of PFS for the MCL patients who achieve it. However, the
same concept does not seem to apply when the same modality is
used as an in vivo purging prior to stem cell collection and ASCT
[54], warranting further clinical investigation in this setting.
Furthermore, since promising results have recently been observed
response-wise with intensive regimens such as hyper-CVAD
alone [55] or combined with rituximab [56], it is still possible that
the further development of combined modality treatments of this
kind may prove reasonably successful in MCL management.
Following a different approach, Lefrere et al. [57], apart from
confirming the extremely poor response rate of MCL patients to
CHOP alone, have shown that sequential CHT based on the
administration of the DHAP regimen to all patients who do not
achieve a CR with CHOP allows many more patients to proceed to
HDCT in CR. However, the big problem is once again that it is
still not clear at all whether HDCT followed by ASCT exerts any
impact on the outcome of MCL patients. Perhaps a good way to
answer this last question might be to intensify the high-dose con-
ditioning regimen of ASCT by integrating it with a radiolabeled,
anti-CD20 monoclonal antibody such as tositumomab. In this
respect, the preliminary results recently reported by Gopal et al.
[58] of 3-year OS of 91% and PFS of 61% justify a cautious hope.
A review from the European Blood and Marrow Transplant
Registry based on the Autologous Blood and Marrow Transplant
Registry for patients with MCL transplanted between 1988 and
1998 has recently been published by Vanderberghe et al. [59]. Of
340 patients identified, as many as 195 had analyzable data after
record review, including 42 (21%) who had undergone ASCT in
first CR. Patients transplanted in first CR had a significantly better
outcome than those transplanted in any other remission status. In
particular, patients transplanted in first CR featured an OS of 88%
at 2 years and 65% at 5 years, as well as a PFS of 65% and 52%,
respectively. Early patients, that is >60 years old, faired considerably
worse than younger patients. Long-term follow-up is obviously
required to both assess the impact of this treatment and to fully
evaluate its curative potential [54].
Finally, standard CHT treatment followed by anti-idiotype (Id)
vaccination deserves consideration as another important option
for investigation in MCL. According to preliminary data, the most
advanced phase II clinical trial, sponsored by the National Cancer
Institute (NCI), is indeed showing encouraging and partially
unexpected findings [60]. In particular, the addition of rituximab
to the EPOCH regimen and the early Id vaccination following
CHT completion seems to interfere only partially with the Id
vaccine’s capability of eliciting specific humoral responses. This
fact is very important, because as it is not yet known what is the
real therapeutic role played by either the humoral and/or the cellular
immune response, until now it was thought that B-cell depletion
caused by rituximab might hinder the overall Id vaccine effective-
ness [61].
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Follicular lymphoma
As nobody yet dares to envision a therapeutic strategy capable of
curing an acceptable proportion of FL patients, the current state-
of-the-art reflects the tendency to focus such efforts mainly
towards four options: conventional CHT, HDCT followed by
ASCT, allogeneic SCT and immunotherapy.
As far as conventional CHT is concerned, results remain
extremely disappointing, and even the data from Lynch et al. [62]
on the impact exerted by an induction combination of fludarabine
and interferon-α-2a, followed by maintenance therapy with the
latter, seem to confirm this overall impression.
However, not much can yet be said in favor of HDCT followed
by ASCT either [63]. In particular, the data from Williams et al.
[64], comparing in a case–control fashion the post-ASCT out-
come of patients with de novo FL, transformed FL and de novo
aggressive NHL, show no significant differences between the
three groups, as well as overall results being far from satisfactory.
On the other hand, allogeneic SCT is mostly considered, as a
therapeutic weapon, as intriguing, given the fact that it may possibly
cure a patient, and as risky, owing to the considerable high death
rate associated with it. The latter is, of course, the main reason for
all such trials ending up enrolling a limited number of patients over
a generally extended period of time. The study by Forrest et al. [65]
is no exception to this trend. Over 8 years, as many as 24 patients
with progressive FL underwent conventional conditioning and
allogeneic SCT. Five early deaths were recorded, four of which
were directly dependent upon the transplant procedure. Meanwhile,
with a median follow-up of nearly 2.5 years, no surviving patient
has yet relapsed. However, much more compelling appears to be
the data from Khouri et al. [66], who with similar features in terms
of both short follow-up and a small number of patients, although
enrolled over a much shorter period of time, are basically repro-
ducing the same clinical results without experiencing such a critical
transplant-related mortality. Since the major difference between
the two trials lies in the use of a non-myeloablative, reduced-con-
ditioning regimen in the latter, there is no doubt that this relatively
new way to manage FL therapeutically might soon prove decisive.
The field that is currently under more pressure, as far as the
quest for a cure for FL is concerned, is that of immunotherapy. It is
here that basic and clinical investigations seem to meet almost on
a daily basis to close the gap that still exists between our know-
ledge and the possibility of consistently curing FL patients.
The fact that rituximab alone does not cure FL, but that it can be
useful and effective in several FL patients, particularly those with
low tumor burden and those for any reasons not immediately
undergoing Id vaccine therapy, appears to have been established
[60, 67, 68]. Moreover, very interesting results have been also
reported on the capability of rituximab, sequentially added to
CHOP, to greatly increase the number of previously untreated FL
patients achieving a molecular response and, thereby, to improve
their RFS [69]. Moreover, Czuczman et al. [70] treated 40 patients
with concurrent rituximab and CHOP, achieving objective remis-
sions in 95% of patients, including 55% CR. No unexpected toxicity
was observed as an effect of the combined modality treatment, and
the median time to progression was not reached after 50 months of
follow-up. In contrast, it is still not possible to fully evaluate the
possible impact of combined immunotherapy with rituximab and
interleukin-2 for relapsed or refractory FL patients [71].
To date, the next immunotherapeutic approach in line for deliv-
ering clinical answers to clinical questions appears to be radio-
immunotherapy, that is the intravenous administration of mono-
clonal antibodies, mainly still anti-CD20, conjugated with radio-
nuclides such as 131I (tositumomab) and 90Y (ibritumomab). For
the time being, probably due to a lower side-effect and toxicity
intensity, the latter seems capable of outpacing the former, at least
in terms of the number and type of trials being conducted and pub-
lished. The bulk of evidence accumulated in favor of expanding
the usage of ibritumomab in FL patients includes: (i) its safe and
significant clinical activity in relapsed or refractory FL patients
with mild thrombocytopenia [72]; (ii) its capability of inducing
significantly better OR and CR rates than rituximab in relapsed or
refractory FL patients [73]; and (iii) its effectiveness even in most
rituximab-refractory FL patients [74]. On the other hand, in the
absence of any comparative study between the two radiolabeled
monoclonal antibodies, tositumomab has also shown substantial
activity in FL patients, perhaps with a worse toxicity profile [75].
The same Id vaccine therapy that a decade ago showed, for the
first time, that it was possible to immunize a cancer patient with an
antigen of his own tumor [76] has now entered the arena of phase
III clinical trials. Only the two such trials currently ongoing, spon-
sored by the NCI and Genitope, respectively, will be able to, once
and for all, demonstrate whether Id vaccine clinical activity [77,
78] is correlated with better prognosis for previously untreated FL
patients [79]. Meanwhile, other phase II clinical trials are also
either concluded or ongoing. Among them are that sponsored by
the Stanford University, on the possible improvement of the Id
vaccine formulation by using Id-pulsed dendritic cells [80], and
that sponsored by the University of Navarra, aiming at verifying
whether Id vaccine may still be of substantial help for first-relapse
FL patients [61].
Finally, despite all this great attention to treatment innovation,
the search for a truly FL-suitable, independent prognostic index
remains active [4, 81].
Extranodal marginal-zone B-cell lymphoma of 
MALT-type
The group of mucosa-associated lymphoid tissue (MALT) NHLs
comprises a number of low-grade extranodal B-cell lymphomas
that share similar clinical, pathological, immunological and
molecular features. This condition has been widely accepted only
in recent years, and has been included in the REAL/WHO classifi-
cation as a specific entity, the ‘extranodal marginal-zone B-cell
lymphoma of MALT-type’ (MALT lymphoma) [1, 2].
The origin of MALT lymphoma is an accumulation of auto-
reactive lymphoid tissue in mucosa or organs that contains no
organized lymphoid tissue [82, 83]. The first required step is the
recruitment of B and T lymphocytes into either the mucosa or
organs that do not correspond to peripheral sites of the immune
system. The acquisition of this organized lymphoid tissue, called
MALT, is induced by a series of antigens, and is probably different
for each organ.
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This particular pathogenesis of MALT lymphoma, with a possible
external (environmental or autoimmune) event as the starting
point of the disease and with the preferential homing of the neo-
plastic cells, induces a particular behavior unique among lympho-
mas, which was described by Isaacson as the MALT concept [84,
85]. Regarding this concept, it is now understood that MALT
lymphomas can arise synchronously or metachronously in various
distinct extranodal sites, and possibly in multiple MALT and/or
non-MALT sites.
Far from being rare, MALT lymphoma accounts for ∼7–8% of
all NHLs, being the third most frequent histological subtype after
DLBCL and FL. The stomach is the most common and best-studied
site of involvement [86]. MALT lymphomas have also been
described in various non-gastrointestinal sites, such as salivary
gland, thyroid, skin, conjuctiva, orbit, larynx, lung, breast, kidney,
liver and prostate [87–101].
There are few published studies specifically reporting treatment
outcome for MALT lymphoma, and even the more recent among
them often refer to retrospective series of RT and CHT, with no
significant difference in outcome between patients who received
different initial treatments. The OS rates range between 80% and
95% at 5 years, but the PFS is significantly shorter, especially for
patients presenting with advanced stage or unfavorable IPI score
[102, 103].
For localized gastric MALT lymphoma, there is increasing
evidence indicating that antibiotics can be effectively employed as
the sole initial treatment: indeed, more than half of the treated
patients achieve a histological regression of the gastric lymphoma
following eradication of Helicobacter pylori [104]. In this con-
text, recent advances in the knowledge of both genetic and
molecular features of MALT lymphoma will probably exert a
fundamental role in refining the clinical management of the
disease. First and foremost, it has been shown that the presence of
t(11;18) does correlate with antibiotic resistance [105, 106],
progression to a more aggressive tumor and higher potential for
local infiltration and distant spread [107–109].
In contrast, no treatment guidelines exist for the management of
patients with non-gastric lymphoma, for those with gastric MALT
lymphoma who fail antibiotic treatment or for the subset of gastric
cases in which no evidence of H. pylori can be found. A choice can
be made between conventional oncological modalities, including
CHT, RT and surgery, each of them alone or in combination.
However, Conconi et al. [110] recently reported interesting data
on the role of rituximab in gastric MALT lymphoma; therefore,
the next reasonable step for H. pilori-positive MALT lymphoma
is the evaluation of a sequential treatment including antibiotics
and rituximab, with the goal of possibly curing most patients.
Conclusion
All in all, it is increasingly evident that lymphoma treatment
choice should be as case-tailored as possible, taking into account
the site, the stage and both clinical and biological characteristics
of the individual patient.
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